Klinische StudieKlinische Studie (Phase III)Randomisierte kontrollierte Studie
Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?
Nature Clinical Practice Oncology · 2005-03 · 2 (3) · 134-135
DOI: 10.1038/ncponc0104 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Nature Clinical Practice Oncology, 2005-03. Verfasst von Stephen T Sonis. Beteiligte Einrichtung: Brigham and Women's Hospital, Boston, MA 02115, USA. ssonis@partners.org. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDouble-Blind MethodEtoposideFibroblast Growth Factor 7Fibroblast Growth FactorsHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousMouth MucosaRadiation InjuriesSeverity of Illness IndexStomatitisTreatment OutcomeWhole-Body Irradiation
Substanzen
FGF7 protein, humanFibroblast Growth Factor 7Fibroblast Growth FactorsEtoposideCyclophosphamide
Autor:innen und Institutionen
- Brigham and Women's Hospital, Boston, MA 02115, USA. ssonis@partners.org
Zitieren
APA
Sonis, S. T. (2005). Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?. Nature Clinical Practice Oncology, 2(3), 134-135. https://doi.org/10.1038/ncponc0104
Vancouver
Sonis ST. Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?. Nature Clinical Practice Oncology. 2005;2(3):134-135. doi:10.1038/ncponc0104
BibTeX
@article{Sonis2005,
author = {Sonis, Stephen T},
title = {Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?},
journal = {Nature Clinical Practice Oncology},
year = {2005},
volume = {2},
number = {3},
pages = {134--135},
doi = {10.1038/ncponc0104}
}
EUVIMED